
### [MONDO:0019247](http://purl.obolibrary.org/obo/MONDO_0019247)
**Label:** combined hyperlipidemia

**Subclasses:** [MONDO:0018473](http://purl.obolibrary.org/obo/MONDO_0018473) (hyperlipoproteinemia type 3), [MONDO:0007759](http://purl.obolibrary.org/obo/MONDO_0007759) (hyperlipidemia, familial combined), 

**Corr. equiv. classes:** [OMIM:144250](http://purl.obolibrary.org/obo/OMIM_144250), [Orphanet:412](http://www.orpha.net/ORDO/Orphanet_412), 

**Class expressions from DL-Learner:**

- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0200036](http://purl.obolibrary.org/obo/HP_0200036) (Skin nodule) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0100261](http://purl.obolibrary.org/obo/HP_0100261) (Abnormal tendon morphology) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0030962](http://purl.obolibrary.org/obo/HP_0030962) (Abnormal morphology of the great vessels) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0030669](http://purl.obolibrary.org/obo/HP_0030669) (Abnormal morphology of the ocular adnexa) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0012397](http://purl.obolibrary.org/obo/HP_0012397) (Aortic atherosclerosis) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0012210](http://purl.obolibrary.org/obo/HP_0012210) (Abnormal renal morphology) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0011842](http://purl.obolibrary.org/obo/HP_0011842) (Abnormality of skeletal morphology) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0010981](http://purl.obolibrary.org/obo/HP_0010981) (Hypolipoproteinemia) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0010935](http://purl.obolibrary.org/obo/HP_0010935) (Abnormality of the upper urinary tract) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0010932](http://purl.obolibrary.org/obo/HP_0010932) (Abnormality of nucleobase metabolism) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0010874](http://purl.obolibrary.org/obo/HP_0010874) (Tendon xanthomatosis) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0010732](http://purl.obolibrary.org/obo/HP_0010732) (Nodular changes affecting the eyelids) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0005181](http://purl.obolibrary.org/obo/HP_0005181) (Premature coronary artery disease) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0004950](http://purl.obolibrary.org/obo/HP_0004950) (Peripheral arterial stenosis) 75.00%
- [HP:0002635](http://purl.obolibrary.org/obo/HP_0002635) (Atheromatosis) and [HP:0004943](http://purl.obolibrary.org/obo/HP_0004943) (Accelerated atherosclerosis) 75.00%


